Company-wide revenue
Reported revenue in 2021 ¥414.42M Reported revenue in 2025 ¥387.62M
- growth amount
- −¥26.8M
- growth annualized
- -1.7%
- growth total
- -6.5%
Japanese company profile · 4576
D.Western Therapeutics Institute, Inc.
In its FY2025 public filing, D.Western Therapeutics Institute, Inc. reports Drug Discovery. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: 株式会社デ・ウエスタン・セラピテクス研究所
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
D.Western Therapeutics Institute, Inc.'s largest reported business by revenue in FY2025 was Drug Discovery.
FY2025 · fiscal year ended December 2025 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended December 2025. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Drug Discovery
- 創薬事業
- Sales
- 売上高
- Operating profit
- 営業利益
Original Japanese label
- Drug Discovery
- 創薬事業
- Sales
- 売上高
- Operating profit
- 営業利益
Reported Sales by business over time
Reported Sales by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Drug Discovery | ¥414.42M | ¥448.1M | ¥428.36M | ¥471.58M | ¥387.62M |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
Business revenue growth
Drug Discovery
Reported revenue in 2021 ¥414.42M Reported revenue in 2025 ¥387.62M
- growth amount
- −¥26.8M
- growth annualized
- -1.7%
- growth total
- -6.5%
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended December 2025
The source document may be in Japanese.
Filing ID: S100XS4G
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.